Global Recombinant FVIII 麻豆原创 Research Report 2024

Publication ID:

PB502244187

Publication Date:

February 26, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Recombinant FVIII
The global Recombinant FVIII market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents鈥� wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Recombinant FVIII, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant FVIII.
Report Scope
The Recombinant FVIII market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant FVIII market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant FVIII manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Bayer
Baxter
Comirnaty
Novo Nordisk
Green Cross
Sinocelltech
Segment by Type
250 IU/bottle
500 IU/bottle
1000 IU/bottle
2000 IU/bottle
Segment by Application
Teenagers
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant FVIII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant FVIII in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant FVIII 麻豆原创 Overview
1.1 Product Overview and Scope of Recombinant FVIII
1.2 Recombinant FVIII Segment by Type
1.2.1 Global Recombinant FVIII 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 250 IU/bottle
1.2.3 500 IU/bottle
1.2.4 1000 IU/bottle
1.2.5 2000 IU/bottle
1.3 Recombinant FVIII Segment by Application
1.3.1 Global Recombinant FVIII 麻豆原创 Value by Application: (2024-2030)
1.3.2 Teenagers
1.3.3 Adults
1.4 Global Recombinant FVIII 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Recombinant FVIII Revenue 2019-2030
1.4.2 Global Recombinant FVIII Sales 2019-2030
1.4.3 Global Recombinant FVIII 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant FVIII 麻豆原创 Competition by Manufacturers
2.1 Global Recombinant FVIII Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Recombinant FVIII Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Recombinant FVIII Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant FVIII Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant FVIII, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant FVIII, Product Type & Application
2.7 Recombinant FVIII 麻豆原创 Competitive Situation and Trends
2.7.1 Recombinant FVIII 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant FVIII Players 麻豆原创 Share by Revenue
2.7.3 Global Recombinant FVIII 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant FVIII Retrospective 麻豆原创 Scenario by Region
3.1 Global Recombinant FVIII 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant FVIII Global Recombinant FVIII Sales by Region: 2019-2030
3.2.1 Global Recombinant FVIII Sales by Region: 2019-2024
3.2.2 Global Recombinant FVIII Sales by Region: 2025-2030
3.3 Global Recombinant FVIII Global Recombinant FVIII Revenue by Region: 2019-2030
3.3.1 Global Recombinant FVIII Revenue by Region: 2019-2024
3.3.2 Global Recombinant FVIII Revenue by Region: 2025-2030
3.4 North America Recombinant FVIII 麻豆原创 Facts & Figures by Country
3.4.1 North America Recombinant FVIII 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant FVIII Sales by Country (2019-2030)
3.4.3 North America Recombinant FVIII Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant FVIII 麻豆原创 Facts & Figures by Country
3.5.1 Europe Recombinant FVIII 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant FVIII Sales by Country (2019-2030)
3.5.3 Europe Recombinant FVIII Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant FVIII 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Recombinant FVIII 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant FVIII Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant FVIII Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Recombinant FVIII 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Recombinant FVIII 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant FVIII Sales by Country (2019-2030)
3.7.3 Latin America Recombinant FVIII Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant FVIII 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant FVIII 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant FVIII Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant FVIII Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant FVIII Sales by Type (2019-2030)
4.1.1 Global Recombinant FVIII Sales by Type (2019-2024)
4.1.2 Global Recombinant FVIII Sales by Type (2025-2030)
4.1.3 Global Recombinant FVIII Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Recombinant FVIII Revenue by Type (2019-2030)
4.2.1 Global Recombinant FVIII Revenue by Type (2019-2024)
4.2.2 Global Recombinant FVIII Revenue by Type (2025-2030)
4.2.3 Global Recombinant FVIII Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Recombinant FVIII Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant FVIII Sales by Application (2019-2030)
5.1.1 Global Recombinant FVIII Sales by Application (2019-2024)
5.1.2 Global Recombinant FVIII Sales by Application (2025-2030)
5.1.3 Global Recombinant FVIII Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Recombinant FVIII Revenue by Application (2019-2030)
5.2.1 Global Recombinant FVIII Revenue by Application (2019-2024)
5.2.2 Global Recombinant FVIII Revenue by Application (2025-2030)
5.2.3 Global Recombinant FVIII Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Recombinant FVIII Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Corporation Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bayer Recombinant FVIII Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Baxter
6.2.1 Baxter Corporation Information
6.2.2 Baxter Description and Business Overview
6.2.3 Baxter Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Baxter Recombinant FVIII Product Portfolio
6.2.5 Baxter Recent Developments/Updates
6.3 Comirnaty
6.3.1 Comirnaty Corporation Information
6.3.2 Comirnaty Description and Business Overview
6.3.3 Comirnaty Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Comirnaty Recombinant FVIII Product Portfolio
6.3.5 Comirnaty Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk Recombinant FVIII Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Green Cross
6.5.1 Green Cross Corporation Information
6.5.2 Green Cross Description and Business Overview
6.5.3 Green Cross Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Green Cross Recombinant FVIII Product Portfolio
6.5.5 Green Cross Recent Developments/Updates
6.6 Sinocelltech
6.6.1 Sinocelltech Corporation Information
6.6.2 Sinocelltech Description and Business Overview
6.6.3 Sinocelltech Recombinant FVIII Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sinocelltech Recombinant FVIII Product Portfolio
6.6.5 Sinocelltech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant FVIII Industry Chain Analysis
7.2 Recombinant FVIII Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant FVIII Production Mode & Process
7.4 Recombinant FVIII Sales and 麻豆原创ing
7.4.1 Recombinant FVIII Sales Channels
7.4.2 Recombinant FVIII Distributors
7.5 Recombinant FVIII Customers
8 Recombinant FVIII 麻豆原创 Dynamics
8.1 Recombinant FVIII Industry Trends
8.2 Recombinant FVIII 麻豆原创 Drivers
8.3 Recombinant FVIII 麻豆原创 Challenges
8.4 Recombinant FVIII 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Bayer
Baxter
Comirnaty
Novo Nordisk
Green Cross
Sinocelltech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.